Drug Development for Hepatocellular Carcinoma: Knowing the Past Helps to Understand the Future-Reference-Cited by-同舟云学术

Drug Development for Hepatocellular Carcinoma: Knowing the Past Helps to Understand the Future

Published:2014-09-15 Issue:11 Volume:19 Page:1115-1117
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Chan Stephen L.¹

Affiliation:

1. State Key Laboratory in Oncology in South China, Sir Y.K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, People's Republic of China

Abstract

Hepatocellular carcinoma (HCC) is a highly complicated disease characterized by comorbid cirrhosis and disease heterogeneity. Given multiple failures in the past, we need to learn from previous experiences and generate novel ideas to increase the chance of success. More effort and patience should be exercised in the selection of a homogeneous patient population and identification of predictive markers during drug development for HCC.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2014-0304

Reference22 articles.

1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

3. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial;Cheng;J Clin Oncol,2013

4. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study;Johnson;J Clin Oncol,2013

5. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study;Llovet;J Clin Oncol,2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vivo and In Vitro Models of Hepatocellular Carcinoma: Current Strategies for Translational Modeling;Cancers;2021-11-08

2. Genetically Engineered Mouse Models for Liver Cancer;Cancers;2019-12-19

3. Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment;Cancers;2019-10-02

4. β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1;Scientific Reports;2016-02

5. Infection and Cancer: The Case of Hepatitis B;Journal of Clinical Oncology;2016-01